Success Metrics

Active Trials
7(88%)

Phase Distribution

Ph phase_1
5
63%
Ph phase_2
3
38%

Phase Distribution

5

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
5(62.5%)
Phase 2Efficacy & side effects
3(37.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

8

all time

Status Distribution
Active(8)

Detailed Status

Recruiting4
Active, not recruiting3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
7
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 15 (62.5%)
Phase 23 (37.5%)

Trials by Status

active_not_recruiting338%
not_yet_recruiting113%
recruiting450%

Recent Activity

7 active trials
Showing 5 of 8
recruitingphase_2

An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer

NCT06938282
recruitingphase_2

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

NCT06770452
active_not_recruitingphase_1

HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma

NCT06773130
recruitingphase_1

Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma

NCT06427239
not_yet_recruitingphase_2

Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer

NCT07503639
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06938282Phase 2

An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer

Recruiting
NCT06770452Phase 2

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

Recruiting
NCT06773130Phase 1

HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma

Active Not Recruiting
NCT06427239Phase 1

Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma

Recruiting
NCT07503639Phase 2

Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer

Not Yet Recruiting
NCT06520488Phase 1

A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors

Recruiting
NCT06385678Phase 1

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Active Not Recruiting
NCT05533463Phase 1

Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Active Not Recruiting

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8